MARKET

CERS

CERS

Cerus
NASDAQ
1.993
-0.067
-3.27%
Opening 13:22 01/02 EST
OPEN
2.060
PREV CLOSE
2.060
HIGH
2.080
LOW
1.970
VOLUME
557.20K
TURNOVER
--
52 WEEK HIGH
2.260
52 WEEK LOW
1.120
MARKET CAP
382.77M
P/E (TTM)
-23.4988
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CERS last week (1222-1226)?
Weekly Report · 12/29/2025 09:37
TD Cowen views Cerus’ IFC franchise as ‘underappreciated’ growth engine
TipRanks · 12/23/2025 18:45
Analysts’ Top Healthcare Picks: Cerus (CERS), Entera Bio (ENTX)
TipRanks · 12/23/2025 18:10
Weekly Report: what happened at CERS last week (1215-1219)?
Weekly Report · 12/22/2025 09:37
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 12/16/2025 14:19
Weekly Report: what happened at CERS last week (1208-1212)?
Weekly Report · 12/15/2025 09:40
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 12/11/2025 11:30
After-Hours Gainers: Biotech Stocks Climb On Data Anticipation And Momentum Buying
NASDAQ · 12/11/2025 04:49
More
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Webull offers Cerus Corp stock information, including NASDAQ: CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.